Peptide Based Metabolic Disorders Therapeutics Market Report 2026

Peptide Based Metabolic Disorders Therapeutics Market Overview

• Peptide Based Metabolic Disorders Therapeutics market size has reached to $34.1 billion in 2025 • Expected to grow to $63.7 billion in 2030 at a compound annual growth rate (CAGR) of 13% • Growth Driver: Obesity Rise Driving Growth In Peptide-Based Metabolic Disorders Therapeutics • Market Trend: Innovative Developments In Peptide-Based Therapeutics Biosimilars • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Peptide Based Metabolic Disorders Therapeutics Market?

Peptide-based metabolic disorder therapeutics refer to pharmaceutical treatments derived from peptides short chains of amino acids that target and modulate biological pathways involved in metabolic disorders such as diabetes, obesity, and related conditions. These therapies are designed to regulate hormone levels, enhance insulin sensitivity, control appetite, and manage glucose metabolism, aiming to improve patient outcomes and quality of life. The main types of drugs in peptide-based metabolic disorders include liraglutide, exenatide, and others. Liraglutide is a type of drug known as a glucagon-like peptide-1 (GLP-1) receptor agonist, which mimics the action of natural GLP-1, a hormone that regulates blood sugar levels by stimulating insulin secretion and inhibiting glucagon release. It is applied for lysosomal storage diseases, diabetes, obesity, hypercholesterolemia, and others. The distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Peptide Based Metabolic Disorders Therapeutics Market Growth Forecast?

The peptide based metabolic disorders therapeutics market size is expected to see rapid growth in the next few years. It will grow to $63.7 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to expanding global obesity burden, increasing adoption of semaglutide and next-generation peptides, rising investment in metabolic disorder drug pipelines, growing demand for long-term weight management solutions, advancements in peptide drug delivery systems. Major trends in the forecast period include rising adoption of glp-1 receptor agonist therapies, growing focus on peptide-based obesity management, expansion of long-acting injectable peptide formulations, increasing use of combination peptide therapies, rising demand for patient-friendly metabolic treatments.

Global Peptide Based Metabolic Disorders Therapeutics Market Segmentation

1) By Drug Type: Liraglutide, Exenatide, Other Drug Type 2) By Application: Lysosomal Storage Diseases, Diabetes, Obesity, Hypercholesterolemia, Other Applications 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Liraglutide: Brand: Saxenda, Brand: Victoza, Generic Liraglutide, Liraglutide For Type 2 Diabetes, Liraglutide For Obesity 2) By Exenatide: Brand: Byetta, Brand: Bydureon, Exenatide For Type 2 Diabetes, Extended-Release Exenatide, Generic Exenatide 3) By Other Drug Type: Semaglutide, Dulaglutide, Albiglutide, Lixisenatide, GLP-1 Receptor Agonists, Pramlintide, Other Peptide-Based Drugs For Metabolic Disorders

What Is The Driver Of The Peptide Based Metabolic Disorders Therapeutics Market?

The rising prevalence of obesity is expected to propel the growth of the peptide-based metabolic disorders therapeutic market going forward. Obesity is a medical condition characterized by excessive body fat accumulation that poses a health risk. The increasing cases of obesity are due to sedentary lifestyles, unhealthy dietary habits, genetic predisposition, and environmental influences promoting calorie-rich diets and physical inactivity. Peptide-based metabolic disorders therapeutics aim to manage conditions such as obesity by leveraging peptides to regulate metabolic functions, improve insulin sensitivity, and control appetite, thereby enhancing patient health outcomes and reducing long-term health risks associated with these chronic disorders. For instance, in December 2024, according to the Office for Health Improvement and Disparities, a UK-based government department From 2022 to 2023, the proportion of women recorded as living with obesity in early pregnancy was 25.4%, which increased slightly to 26.2% from 2023 to 2024. Therefore, the rising prevalence of obesity is driving the peptide-based metabolic disorder therapeutics market.

Key Players In The Global Peptide Based Metabolic Disorders Therapeutics Market

Major companies operating in the peptide based metabolic disorders therapeutics market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Ipsen S.A., Pfizer Inc., Merck & Co. Inc., Johnson & Johnson, AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Amgen Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Amarin Corporation plc

Global Peptide Based Metabolic Disorders Therapeutics Market Trends and Insights

Major peptide-based metabolic disorders therapeutics market companies are developing innovative peptide-based treatments, such as anti-diabetic biosimilars, to address unmet medical needs and expand patient treatment options. Peptide-based anti-diabetic biosimilars refer to therapeutic drugs that mimic existing peptide-based therapies for diabetes, offering comparable efficacy and safety profiles to established medications while potentially lowering treatment costs through competitive pricing strategies. For instance, in January 2024, Glenmark Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Lirafit, a biosimilar version of the popular anti-diabetic drug Liraglutide in India. It belongs to the class of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). This class of drugs mimics the action of the naturally occurring GLP-1 hormone, which is crucial in regulating blood sugar levels. This biosimilar has undergone clinical trials demonstrating its effectiveness in lowering glycemic parameters, promoting weight reduction, and enhancing cardiovascular safety. These are crucial benefits for managing diabetes and associated conditions such as obesity and cardiovascular diseases.

What Are Latest Mergers And Acquisitions In The Peptide Based Metabolic Disorders Therapeutics Market?

In December 2023, Roche Holding AG, a Switzerland-based healthcare company, acquired Carmot Therapeutics Inc. for $2.7 billion. With this acquisition, Roche gains access to its clinical-stage incretins like CT-388, a dual GLP-1/GIP receptor agonist in Phase 2 trials with the potential for treating obesity in diabetic and non-diabetic patients. Carmot Therapeutics Inc. is a clinical-stage biotechnology company specializing in peptide-based therapeutics for metabolic disorders such as diabetes and obesity.

Regional Insights

North America was the largest region in the peptide based metabolic disorders therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Peptide Based Metabolic Disorders Therapeutics Market?

The peptide-based metabolic disorders therapeutics market consists of sales of semaglutide, dulaglutide, albiglutide, and pramlintide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Peptide Based Metabolic Disorders Therapeutics Market Report 2026?

The peptide based metabolic disorders therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the peptide based metabolic disorders therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.